VANCOUVER, British Columbia, May 20, 2026
Optimi Health Corp. has announced the pricing of an oversubscribed US$15 million underwritten public offering in connection with the company’s planned uplisting to the Nasdaq Capital Market, marking a major financial and commercial milestone for the rapidly growing psychedelic pharmaceutical sector. The company’s common shares are expected to begin trading on Nasdaq under the ticker symbol “OPTH”, strengthening Optimi Health’s visibility among global biotechnology and pharmaceutical investors.
The commercial-stage pharmaceutical company, which focuses on manufacturing and distributing GMP-grade psychedelic drug products, stated that it is offering 2.4 million common shares priced at US$6.25 per share, with the underwriter also receiving the option to purchase additional shares. The gross proceeds from the offering are expected to total approximately US$15 million, excluding potential exercise of the underwriter’s additional share option.
Industry analysts view the Nasdaq uplisting as a major validation milestone for the emerging psychedelic therapeutics industry, particularly as investor interest continues growing around regulated mental health therapies involving compounds such as MDMA and psilocybin.
Nasdaq Uplisting Expands Growth Opportunities
Optimi Health stated that proceeds from the offering will primarily support expansion of manufacturing operations, distribution capabilities, international market growth, and broader commercialization activities, including planned expansion into the United States market. The company also intends to use funding for working capital, operational growth initiatives, and scaling production of its psychedelic pharmaceutical products.
Advertisement
The uplisting to Nasdaq significantly increases Optimi Health’s access to institutional capital markets while improving exposure to U.S. biotechnology investors. Healthcare investment experts note that Nasdaq listings often provide growth-stage pharmaceutical companies with enhanced financing flexibility, improved liquidity, and stronger long-term market credibility.
The offering was managed by Joseph Gunnar & Co., LLC, acting as sole book-running manager. According to the company, the registration statement related to the public offering was declared effective by the U.S. Securities and Exchange Commission (SEC) on May 19, 2026.
Optimi Health also confirmed completion of a previously announced common share consolidation designed to support the Nasdaq uplisting process and align with listing requirements.
Psychedelic Pharmaceutical Market Continues Rapid Expansion
Optimi Health operates as a commercial-stage pharmaceutical manufacturer specializing in GMP-compliant psychedelic drug products intended for regulated clinical and therapeutic programs. The company currently manufactures validated MDMA and botanical psilocybin drug products from its licensed pharmaceutical facilities located in British Columbia, Canada.
Psychedelic-assisted therapies have become one of the fastest-growing sectors in mental health research as clinical studies continue evaluating compounds such as psilocybin and MDMA for treatment-resistant depression, post-traumatic stress disorder (PTSD), anxiety disorders, addiction, and other psychiatric conditions.
Optimi Health supplies both active pharmaceutical ingredients (APIs) and finished dosage formulations to international clinical programs operating within regulated frameworks. The company noted that its products are already prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible within Canada through the Special Access Program.
Industry experts believe regulatory momentum supporting psychedelic therapeutics has accelerated substantially over the past several years as mental health disorders continue rising globally and conventional treatment limitations create demand for alternative therapeutic approaches.
Investor Interest Grows in Psychedelic Biopharma Sector
The oversubscribed nature of the offering reflects growing investor confidence in companies developing regulated psychedelic medicines and scalable pharmaceutical manufacturing infrastructure. Analysts increasingly view GMP manufacturing capabilities as a critical competitive advantage within the psychedelic therapeutics sector because regulatory-grade production remains essential for clinical trials, pharmaceutical approvals, and future commercialization activities.
The global psychedelic drug market is projected to experience substantial growth over the coming decade as more clinical data emerges supporting therapeutic applications across psychiatry and neuroscience. Companies capable of combining regulatory compliance, pharmaceutical-grade manufacturing, and international distribution capabilities are expected to play increasingly important roles within the sector.
Optimi Health’s Nasdaq uplisting highlights broader institutional recognition of psychedelic therapeutics as an evolving segment within the global biopharmaceutical industry. Healthcare market observers expect additional investment activity, strategic partnerships, and clinical expansion initiatives to continue shaping the future of psychedelic medicine commercialization worldwide.
Source: Optimi press release
